ACS CAN Priorities for PDUFA VII Reauthorization

August 21, 2020

Every five years the FDA drug user fees are reauthorized, offering an opportunity to influence priorities.  ACS CAN is recommending an increased focus on patient representation in regulatory decision making, guidance to drive increased use of decentralized trials, and a scientific focus on disparities.